GORE® ENFORM Biomaterial Product Studyfor Hernia, VentralSites in Milwaukee +6 more locationsSponsor: W.L.Gore & AssociatesSex: All·Age: 18+Code: NCT04718168·Recruiting·Listed Jan 2021Apply to this trial
US National TOP Registryfor Lung TransplantSites in Milwaukee +6 more locationsSponsor: TransMedicsSex: All·Age: All agesCode: NCT06513091·Recruiting·Listed Jul 2024Apply to this trial
Evaluation of Potassium (K) and Ionized Calcium (iCa) Tests Using Capillary Specimensfor Hematologic TestsSites in Milwaukee +2 more locationsSponsor: Abbott Point of CareSex: All·Age: 18+·Accepts healthy volunteersCode: NCT07287618·Recruiting·Listed Dec 2025Apply to this trial
Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimensfor Hematologic TestsSites in Milwaukee +2 more locationsSponsor: Abbott Point of CareSex: All·Age: 18+·Accepts healthy volunteersCode: NCT07287631·Recruiting·Listed Dec 2025Apply to this trial
Stimulating the Aging Brain Using Brain and Sensory Stimulationfor Primary Progressive Aphasia1 location in MilwaukeeSponsor: Medical College of WisconsinSex: All·Age: 45+Code: NCT07650188·Recruiting·Listed Jun 2026Apply to this trial
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])for Lung Non-Small Cell CarcinomaSites in Milwaukee, Wauwatosa +623 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020Apply to this trial
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25for Breast CancerSites in Milwaukee, Wauwatosa +1087 more locationsSponsor: NRG OncologySex: Female·Age: 18 - 60Code: NCT05879926·Phase 3·Recruiting·Listed May 2023Apply to this trial
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Diseasefor Stage III Colon CancerSites in Milwaukee, Wauwatosa +923 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021Apply to this trial
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomasfor Intracranial MeningiomaSites in Milwaukee, Wauwatosa +446 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015Apply to this trial
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancerfor Advanced Endometrial CarcinomaDrug: BevacizumabSites in Milwaukee, Sheboygan +266 more locationsSponsor: National Cancer Institute (NCI)Sex: Female·Age: 18+Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025Apply to this trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumabfor Anatomic Stage I Breast Cancer AJCC v8Sites in Milwaukee, Wauwatosa +594 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT06876714·Phase 3·Recruiting·Listed Mar 2025Apply to this trial
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancerfor Advanced Lung Non-Squamous Non-Small Cell CarcinomaDrug: BevacizumabSites in Milwaukee, Waukesha +322 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT04181060·Phase 3·Recruiting·Listed Nov 2019Apply to this trial
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancerfor Anatomic Stage II Breast Cancer AJCC v8Drug: DurvalumabSites in Milwaukee, Wauwatosa +535 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023Apply to this trial
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic LeukemiaSites in Milwaukee, Madison +156 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18 - 39Code: NCT03150693·Phase 3·Recruiting·Listed May 2017Apply to this trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trialfor Metastatic Renal Cell CarcinomaSites in Milwaukee, Menomonee Falls +278 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022Apply to this trial
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Studyfor Muscle Invasive Bladder Urothelial CarcinomaSites in Milwaukee, Wauwatosa +441 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023Apply to this trial
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancerfor Clear Cell Renal Cell CarcinomaSites in Milwaukee, Wauwatosa +401 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024Apply to this trial
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumabfor Anatomic Stage II Breast Cancer AJCC v8Sites in Milwaukee, Wauwatosa +777 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023Apply to this trial
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancerfor Locally Advanced Cervical AdenocarcinomaSites in Milwaukee, Waukesha +318 more locationsSponsor: National Cancer Institute (NCI)Sex: Female·Age: 18+Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025Apply to this trial
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphomafor Classic Follicular LymphomaDrug: MosunetuzumabSites in Milwaukee, Menomonee Falls +258 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06337318·Phase 3·Recruiting·Listed Mar 2024Apply to this trial
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Studyfor Clinical Stage III Cutaneous Melanoma AJCC v8Drug: CabozantinibSites in Milwaukee, Waukesha +202 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT05136196·Phase 2·Recruiting·Listed Nov 2021Apply to this trial
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancerfor Astrocytoma, IDH-Mutant, Grade 3Drug: VorasidenibSites in Milwaukee, Menomonee Falls +115 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 12+Code: NCT07215910·Phase 3·Recruiting·Listed Oct 2025Apply to this trial
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)for Acute Myeloid LeukemiaSites in Milwaukee, Wauwatosa +324 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022Apply to this trial
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphomafor Mantle Cell LymphomaSites in Milwaukee, New Berlin +225 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 60+Code: NCT05976763·Phase 3·Recruiting·Listed Aug 2023Apply to this trial
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapyfor Anaplastic Large Cell Lymphoma, ALK-NegativeSites in Milwaukee, Menomonee Falls +140 more locationsSponsor: Eastern Cooperative Oncology GroupSex: All·Age: 18 - 75Code: NCT06724237·Phase 3·Recruiting·Listed Dec 2024Apply to this trial
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaSites in Milwaukee, Madison +203 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 59Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022Apply to this trial
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trialfor Metastatic Castration-Resistant Prostate CarcinomaSites in Milwaukee, Menomonee Falls +82 more locationsSponsor: Alliance for Clinical Trials in OncologySex: Male·Age: 18+Code: NCT07200830·Phase 3·Recruiting·Listed Oct 2025Apply to this trial
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaDrug: VenetoclaxSites in Milwaukee, Sheboygan +211 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06317649·Phase 2·Recruiting·Listed Mar 2024Apply to this trial
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancerfor Fallopian Tube Endometrioid AdenocarcinomaDrug: BevacizumabSites in Milwaukee, Wauwatosa +653 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024Apply to this trial
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)for Myelodysplastic SyndromeSites in Milwaukee, Madison +136 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06577441·Phase 2·Recruiting·Listed Aug 2024Apply to this trial
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeSites in Milwaukee, Menomonee Falls +78 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03739814·Phase 2·Recruiting·Listed Nov 2018Apply to this trial
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaDrug: VenetoclaxSites in Milwaukee, Appleton +165 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 59Code: NCT05554393·Phase 2·Recruiting·Listed Sep 2022Apply to this trial
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancerfor Locally Advanced Lung Non-Small Cell CarcinomaSites in Milwaukee, Wauwatosa +444 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT05624996·Phase 3·Recruiting·Listed Nov 2022Apply to this trial
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancerfor Locally Advanced Unresectable Pancreatic Ductal AdenocarcinomaSites in Milwaukee, Wauwatosa +324 more locationsSponsor: NRG OncologySex: All·Age: 18+Code: NCT06958328·Phase 3·Recruiting·Listed May 2025Apply to this trial
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)for Acute Myeloid LeukemiaSites in Milwaukee, Sheboygan +127 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06672146·Phase 2·Recruiting·Listed Nov 2024Apply to this trial
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomasfor Metastatic Dedifferentiated LiposarcomaSites in Milwaukee, Wauwatosa +239 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT06422806·Phase 3·Recruiting·Listed May 2024Apply to this trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancerfor Prostate AdenocarcinomaSites in Milwaukee, Wauwatosa +397 more locationsSponsor: NRG OncologySex: Male·Age: 18+Code: NCT05946213·Phase 3·Recruiting·Listed Jul 2023Apply to this trial
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancerfor Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Sites in Milwaukee, Menomonee Falls +104 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT07195734·Phase 2·Recruiting·Listed Sep 2025Apply to this trial
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinomafor Recurrent Head and Neck Squamous Cell CarcinomaSites in Milwaukee, Menomonee Falls +125 more locationsSponsor: National Cancer Institute (NCI)Sex: All·Age: 18 - 79Code: NCT04671667·Phase 2·Recruiting·Listed Dec 2020Apply to this trial
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trialfor Metastatic Colorectal AdenocarcinomaSites in Milwaukee, Wauwatosa +163 more locationsSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT05673148·Phase 2·Recruiting·Listed Jan 2023Apply to this trial